Immunosenescence is the age-related decline and remodeling of the immune system, profoundly influencing susceptibility to ...

Oligonucleotide-based therapeutics represent a frontier in immunology, regenerative medicine, and oncology, offering unparalleled precision in modulating ...

Issued on behalf of GT Biopharma, Inc.After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, ...

If you suffer from eczema, you may have adopted an approach that involves reducing triggers such as detergents, allergens, ...

Operator: Ladies and gentlemen, thank you for joining, and welcome to the Innate Pharma First Quarter 2026 Business Update and Financial Results.

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today ...

Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic ...

Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab plus ...

Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...

INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug ...

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities ...